Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human CD34- hematopoietic stem cells: basic features and clinical relevance.

Kiyoshi Ando1

  • 1Department of Hematology and Rheumatology and Research Center for Cell Transplantation, Tokai University, School of Medicine, Kanagawa, Japan. andok@keyaki.cc.u-tokai.ac.jp

International Journal of Hematology
|June 4, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<b>A new species of <i>Lycidioides</i> Ando (Coleoptera, Tenebrionidae, Stenochiinae) from the Malay Peninsula, with the first record of the genus outside Borneo</b>.

Zootaxa·2026
Same author

<i>Kotodama</i> (): the spirit of words in medicine in Japan.

Journal of medical ethics·2026
Same author

EBV promotes alveolar trabecula resorption via extracellular vesicle remodeling by group IIA secreted phospholipase A<sub>2</sub>.

Journal of lipid research·2026
Same author

A single microRNA miR-195 rescues the arrested B cell development induced by EBF1 deficiency.

eLife·2026
Same author

Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.

Cancer science·2025
Same author

Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.

Japanese journal of clinical oncology·2025

Researchers identified CD34-negative hematopoietic stem cells (CD34 HSCs) in humans. Developing new assays for these CD34 HSCs is crucial for clinical diagnostics and understanding stem cell behavior.

Area of Science:

  • Hematology
  • Stem Cell Biology

Background:

  • CD34 is a standard marker for stem and progenitor cells, utilized in clinical stem cell transplantation (SCT).
  • Recent studies identified CD34-negative hematopoietic stem cells (CD34 HSCs) in both mice and humans, challenging conventional markers.

Purpose of the Study:

  • To investigate the presence and characteristics of human CD34 HSCs.
  • To explore the potential of in vitro generation of CD34+ HSCs from CD34- cells as a surrogate assay.
  • To highlight the need for improved diagnostic methods for CD34 HSCs.

Main Methods:

  • Xenogeneic chimera engraftment assays using immunodeficient mice and preimmune fetal sheep.
  • Analysis of human CD34 HSCs in cord blood, bone marrow, and G-CSF-mobilized peripheral blood.
  • In vitro assessment of clonogenic activity and in vitro generation of CD34+ HSCs from CD34- cells.

Related Experiment Videos

Main Results:

  • Human CD34 HSCs were identified in various blood and tissue sources.
  • No significant in vitro clonogenic activity was detected for CD34 HSCs.
  • An in vitro approach using CD34+ HSC generation from CD34- cells did not reveal a CD34- precursor population in SCT recipients.

Conclusions:

  • The unique characteristics of CD34 HSCs pose challenges for clinical sample assessment.
  • Development of a positive marker and a more efficient in vivo assay for CD34 HSCs is essential.
  • Improved diagnostic evaluation of CD34 HSCs could impact various clinical procedures and disease understanding.